TLR7 and T-cell non-Hodgkin lymphoma: In our murine model of T cell lymphoma, the application of a conventional chemotherapeutic agent, DOX, which is a component of CHOP therapy, in combination with TLR7 agonist SZU-101, significantly improved survival compared with PBS treatment or DOX treatment alone.